IRIS

1,3-Butadiene

CASRN 106-99-0

MUTAGENICITY AND CARCINOGENICITY ASSESSMENT OF 1,3-BUTADIENE

Notice - This site contains archived material(s).

Archive disclaimer
Archived files are provided for reference purposes only. The file was current when produced, but is no longer maintained and may now be outdated. Persons with disabilities having difficulty accessing archived files may contact the NCEA Webmaster for assistance. Please use the contact form if you need additional assistance.

Overview

1,3-Butadiene has been shown to be an indirect mutage in bacteria. Two of its potential metabolites, 3,4- epoxybutene and diepoxybutane, are genotoxic in prokaryote as well as eukaryote test systems. Exposure of rodents to 1,3-butadiene results in ovarian tumors in mice and testicular tumors in rats, which offers suggestive evidence that 1,3-butadiene (or a motabolite of 1,3-butadiene) may reach the germ cells. There is also evidence that the dimer of 1,3-butadiene, 4-vinyl-1-cyclohexene, causes ovarian tumors in mice. The total body of evidence, including metabolism, mutagenicity and carcinogenicity data, suggests that 1,3-butadiene may present a genetic risk to humans. However, mutagenicity studies in mammalian test systems should be conducted to further characterize the mutagenic potential of 1,3-butadiene. On the basis of sufficient evidence from studies in two species of rodents, and inadequate epidemiologic data, 1,3-butadiene can be classified, according to EPA's Proposed Guidelines for Carcinogen Risk Assessment, as a 'probable' human carcinogen, Group B2. Using the classification scheme of the International Agency for Research on Cancer, 1,3-butadiene would be classified as a 'probable' human carcinogen, Group 2B.

Citation

Bayard, S., R. Beliles, A. Chiu, H. Gibb, AND B. Sadler. MUTAGENICITY AND CARCINOGENICITY ASSESSMENT OF 1,3-BUTADIENE. U.S. Environmental Protection Agency, Washington, D.C., EPA/600/8-85/004F (NTIS PB86125507).

Top of Page